Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Appointed C. Evan Ballantyne as Chief Financial Officer in April 2023.
- Appointed C. Evan Ballantyne as Chief Financial Officer in April 2023.
- Obtained a grant in the aggregate amount of $1.3 million (EUR 1.2 million) to a consortium led by Gain Therapeutics for AAT research program.
- Cash, cash equivalents and marketable securities were $18.8 million as of March 31, 2023.
- The Company believes that this amount, together with the proposed research grant funding detailed above and ATM proceeds received in April 2023, will be sufficient to support current operations into the third quarter of 2024.